The main objective of the Investment approach is to generate capital appreciation through investments in equities with a medium to long-term perspective.
| Alpha (1Y) | Beta (1Y) | Standard Deviation (1Y) | % of +ve Months (SI) |
|---|---|---|---|
| -16.24% | 0.63 | 16.19% | 54.79% |
Performance Table #
| Trailing Returns (%) | 1m return | 3m return | 6m return | 1y return | 2y return | 3y return | 5y return | 10y return | Since inception return |
|---|---|---|---|---|---|---|---|---|---|
| Portfolio | -4.30% | -1.30% | 3.40% | -12.30% | 4.70% | 20.60% | 10.90% | - | 9.80% |
| NIFTY PHARMA | -4.20% | -2.90% | 3.60% | -11.40% | -1.20% | 16.10% | 5.50% | - | 1.10% |
QRC Report Card *
| Strategy | Category | Fund Manager | Date of Inception | Age Of PMS | Corpus (in Cr, approx) | Benchmark | Returns SI (CAGR) | Stocks In Portfolio | Sectors In Portfolio |
|---|---|---|---|---|---|---|---|---|---|
| Kotak AMC Pharma Fund | Multi Cap | Anshul Saigal | 20 September 2016 | 6Y 4M | 22 | NIFTY PHARMA | 9.80% | 17 | 3 |
| Portfolio Quality (Q) | Portfolio Risk (R) | Portfolio Consistency (C) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Index | Category Alpha (1Y) | Relative Alpha (1Y) |
% of +ve Months
(Fund Data) |
Alpha (1Y) | Beta (1Y) |
Standard Deviation (1Y)
(Fund Data) |
Sharpe Ratio (1Y)
(Fund Data) |
Alpha (SI) | Information Ratio (SI) | Consistency Ratio % |
| Nifty 50 | 1.84% | -16.59% | 54.79% | -14.75% | 0.62 | 16.19% | -1.32 | -1.39% | -0.08 | 50.68 % |
| Nifty 500 | -0.19% | -16.05% | -16.24% | 0.63 | -1.58% | -0.09 | 52.05 % | |||
| Nifty Midcap 100 | -5.79% | -12.87% | -18.66% | 0.48 | -1.44% | -0.07 | 47.95 % | |||
| Nifty Smallcap 100 | 2.89% | -5.95% | -3.06% | 0.48 | 3.55% | 0.15 | 46.58 % | |||
VIEW DETAILED QUALITY, RISK, CONSISTENCY ANALYSIS
Portfolio Holdings
| Holding | % |
|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD | 23.60 |
| DR REDDY'S LABORATORIES LTD | 14.00 |
| CIPLA LTD | 10.40 |
| INDOCO REMEDIES LTD | 6.10 |
| DIVI'S LABORATORIES LTD | 5.80 |
| IPCA LABORATORIES LTD | 5.70 |
| FORTIS HEALTHCARE LTD | 5.50 |
| ZYDUS LIFESCIENCES LTD | 4.20 |
| ALKEM LABORATORIES LTD | 3.30 |
| TORRENT PHARMACEUTICALS LTD | 3.00 |
| BIOCON LTD | 2.90 |
| ALEMBIC PHARMACEUTICALS LTD | 2.80 |
| LUPIN LTD | 2.60 |
| JB CHEMICALS & PHARMACEUTICALS LTD | 2.60 |
| AUROBINDO PHARMA LTD | 2.30 |
| GLAND PHARMA LTD | 2.10 |
| AJANTA PHARMA LTD | 0.50 |
| Top 17 Equity Holdings | 97.69 |
Sector Allocation
| Holding | % |
|---|---|
| Cash & Cash Equivalent | 3.60 |
| BFSI | 44.20 |
| Information Technology | 52.20 |
Market Cap Allocation
| Allocations | % |
|---|---|
| Large Cap | 56.9 |
| Mid Cap | 28.7 |
| Small Cap | 12 |
| Cash | 2. |
Do Not Simply Invest, Make Informed Decisions
WISH TO MAKE INFORMED INVESTMENTS FOR LONG TERM WEALTH CREATION
Book
a call with our PMS AIF Specialists
Disclaimer
#Returns as of 31 Dec 2022. Returns up to 1 Year are absolute, above 1 Year are CAGR.
*QRC Report Card data is updated quarterly. Current data is as of Sep 22.
